

CLINICAL TRIAL AWARD

Advancing Basic Science into the Clinic:
Are You Ready to Take the Next Step?



Clinical research bridges the gap between the basic research of today and the development and deployment of future therapeutics. The Clinical Trial Award is designed to sponsor promising Phase I or II clinical trials that may accelerate the progression of neurofibromatosis (NF) and Schwannomatosis research from bench to bedside, furthering the **Neurofibromatosis Research Program (NFRP)** mission of enhancing the lives of individuals with these diseases.

Applications must include preliminary data, a clinical protocol, evidence of access to an appropriate patient population and recruitment schedule, a statistical plan, and appropriate Institutional Review Board documents. Proposals for Phase II funding must include pilot or Phase I clinical trial data.

Although there is no total dollar amount restriction, programmatic priority will be given to smaller-scale, cost-effective trials. Funding for Phase I trials can be requested for a maximum of 3 years. Funding for Phase II trials can be requested for up to 4 years. Peer review will emphasize the potential impact of the project on the treatment and/or management of NF and/or Schwannomatosis. See the program announcement for additional criteria.

Proposals Are Due By:
April 25, 2006

This document is a synopsis of details specific to the NFRP Clinical Trial Award. A detailed description of this award mechanism along with specific evaluation criteria, submission requirements, and deadlines are available in the [FY06 NFRP Clinical Trial Award Program Announcement](#) found at:

<http://cdmrp.army.mil>